A landmark study published in the New England Journal of Medicine has revealed promising results…
Childrens Tumor FoundationJune 21, 2024
NF affects 1 in every 2,000 births
NF refers to genetic conditions that cause tumors to grow on nerves throughout the body. NF includes all forms of neurofibromatosis and schwannomatosis and affects about 4 million people worldwide. Anyone can be born with NF, and it affects everyone differently. There is no cure yet.
1
FDA-approved Drug for NF, and more on the horizon
Koselugo (selumetinib). is the first FDA-approved drug for NF. CTF-funded research paved the way to this drug approval, and we are working for more drug approvals for all types of NF!
3X
the number of NF Clinical Trials in the past 10 years
There are currently 67 active clinical trials for NF – three times the number of trials than just ten years ago!
45
years of funding NF research
The Children’s Tumor Foundation was founded 45 years ago as the first grassroots organization to support patients with all types of NF.
11,000
have joined the NF Registry
The NF Registry is a secure website where people with NF can take an active role in the search for better treatments. Participating is easy and makes a difference!
20,000
patients each year visit the NF Clinic Network
The NF Clinic Network (NFCN) is the first nationwide network dedicated to improving clinical care and establishing best practices for treating individuals with NF.
CTF Knowledge Base
What are you looking for?
Search our website for news and information about NF.
Latest News
From Discovery to Impact: How Collaboration Unlocked Brigatinib for NF2-Related Schwannomatosis
A pivotal chapter in the story of drug discovery for NF2-related schwannomatosis has been written…
Give for Hope: Rozalinda’s Challenges with NF2-SWN and Her Hope for Brigatinib
Rozalinda was just 21 years old when she received life-altering news that would reshape her…
From Discovery to Impact: How Collaboration Unlocked Brigatinib for NF2-Related Schwannomatosis
A pivotal chapter in the story of drug discovery for NF2-related schwannomatosis has been written…
New Meningioma model in development in CTF Preclinical Hub Unlocks Opportunities for NF2-SWN Brain Tumor Therapies
Funding from the Children’s Tumor Foundation enables University of Plymouth researchers to pioneer a humanized…
Give for Hope: Rozalinda’s Challenges with NF2-SWN and Her Hope for Brigatinib
Rozalinda was just 21 years old when she received life-altering news that would reshape her…
Stay Up-To-Date
Join our mailing list for news, exclusive resources, events and opportunities.
"*" indicates required fields
